SEMA3B but Not CUL1 as Marker for Pre-Eclampsia Progression
Journal name: The Malaysian Journal of Medical Sciences
Original article title: SEMA3B but Not CUL1 as Marker for Pre-Eclampsia Progression
The Malaysian Journal of Medical Sciences (MJMS) is a peer-reviewed, open-access journal published online at least six times a year. It covers all aspects of medical sciences and prioritizes high-quality research.
This page presents a generated summary with additional references; See source (below) for actual content.
Original source:
This page is merely a summary which is automatically generated hence you should visit the source to read the original article which includes the author, publication date, notes and references.
Tjam Diana Samara, Isabella Kurnia Liem, Ani Retno Prijanti, Andrijono
The Malaysian Journal of Medical Sciences:
(A peer-reviewed, open-access journal)
Full text available for: SEMA3B but Not CUL1 as Marker for Pre-Eclampsia Progression
Year: 2019 | Doi: 10.21315/mjms2019.26.1.6
Copyright (license): CC BY 4.0
Download the PDF file of the original publication
Summary of article contents:
Introduction
Pre-eclampsia (PE) is a pregnancy-related condition characterized by hypertension and proteinuria, occurring typically after 20 weeks of gestation. It affects approximately 2% to 8% of pregnancies and poses significant risks for both maternal and fetal health. The classification of PE into early-onset and late-onset forms reflects differences in etiology, with late-onset PE developing at or after 32 weeks of gestation. One proposed mechanism contributing to PE is an imbalance between pro-angiogenic and anti-angiogenic factors during pregnancy. This study highlights the roles of semaphorin 3B (SEMA3B) as an anti-angiogenic factor and cullin 1 (CUL1) as a pro-angiogenic factor in the context of late-onset PE, examining correlations between their levels in maternal serum and placental tissues.
Correlation Between SEMA3B and CUL1 Levels
The study investigated the serum and placental levels of SEMA3B and CUL1 in 50 patients diagnosed with late-onset PE. Results showed that heightened serum SEMA3B levels were significantly correlated with increased placental SEMA3B levels, suggesting that monitoring maternal serum SEMA3B could serve as a potential marker for tracking PE progression during pregnancy. However, no significant correlation was found between serum and placental levels of CUL1, raising questions about its involvement in the pathology of late-onset PE. This discrepancy emphasizes the importance of understanding the role of these angiogenic factors, particularly how the anti-angiogenic SEMA3B may contribute to the clinical manifestations of PE, while also acknowledging the complexity of angiogenic factor interactions that influence the disease.
Conclusion
The findings of this study suggest that monitoring serum levels of SEMA3B, rather than CUL1, may offer a practical approach for tracking the progression of late-onset pre-eclampsia. The significant positive correlation between maternal serum and placental SEMA3B levels indicates its potential as a biomarker. Though CUL1 may play a role in trophoblast invasion and placental development, further research is necessary to clarify its functional implications in the context of PE. Continued exploration into the dynamics of angiogenic factor balance could enhance understanding of pre-eclampsia's pathophysiology and contribute to the development of effective monitoring and therapeutic strategies.
FAQ section (important questions/answers):
What is the relationship between SEMA3B and pre-eclampsia?
SEMA3B is an anti-angiogenic factor whose elevated levels correlate with impaired trophoblast invasion during pregnancy, leading to complications such as pre-eclampsia.
How was the correlation between SEMA3B and CUL1 studied?
The study involved evaluating serum and placental levels of SEMA3B and CUL1 in 50 late-onset pre-eclampsia patients, finding a significant correlation with SEMA3B but not with CUL1.
What methods were used to analyze SEMA3B and CUL1 levels?
Researchers collected maternal serum and placental samples, employing ELISA kits to measure SEMA3B and CUL1 levels before applying statistical analysis to determine correlations.
What conclusions can be drawn from the study's findings?
The findings suggest that circulating maternal SEMA3B levels can be indicative of pre-eclampsia progression during pregnancy, while CUL1 levels do not show the same predictive value.
Glossary definitions and references:
Scientific and Ayurvedic Glossary list for “SEMA3B but Not CUL1 as Marker for Pre-Eclampsia Progression”. This list explains important keywords that occur in this article and links it to the glossary for a better understanding of that concept in the context of Ayurveda and other topics.
1) Table:
A 'table' in the context of this study most likely refers to the organized presentation of data, listing the characteristics of study participants or results of measurements related to SEMA3B and CUL1 levels in late-onset pre-eclampsia. Tables help provide clear, concise information for analysis and comparison.
2) Study (Studying):
A 'study' refers to the research conducted to investigate the relationship between serum and placental levels of SEMA3B and CUL1 in late-onset pre-eclampsia. This includes the methods used to collect and analyze data, as well as the conclusions drawn regarding these angiogenic factors and their relevance in the disease.
3) Cancer:
Though not the main focus of this research, 'cancer' is relevant as SEMA3B is identified as an inactive tumor suppressor gene in various cancers. Understanding the role of similar biomarkers in other conditions like pre-eclampsia can provide insights into the molecular processes involved in both cancer and pregnancy complications.
4) Blood:
In this context, 'blood' refers to the maternal serum obtained from the participants, which is crucial for measuring SEMA3B and CUL1 levels. Analyzing blood samples allows researchers to investigate potential biomarkers in maternal circulation that may hint at the progression or risk of pre-eclampsia.
5) Line:
The term 'line' could imply a genetic lineage or a cell line used for research, particularly when discussing the implications of SEMA3B and CUL1 in trophoblast invasion and other physiological processes. Understanding the genetic or cellular context enhances insights into implications for maternal-fetal health.
6) Measurement:
'Measurement' is critical in this research as it denotes the quantification of SEMA3B and CUL1 levels. Accurate measurement techniques, like ELISA, are essential to establish reliable data, which consequently affects the analysis, conclusions, and potential clinical applications focused on monitoring and managing pre-eclampsia.
7) Family:
'Family' could refer to the classification of proteins, such as the semaphorin family to which SEMA3B belongs, emphasizing the functional categories of ligands involved in biological processes. Understanding these classifications helps in determining the interaction mechanisms between genes and their protein products in various conditions.
8) Medicine:
'Medicine' is a broad term encompassing the scientific study and clinical application of health-related issues, including pre-eclampsia. This study contributes to the medical field by identifying potential biomarkers that could improve monitoring and treatment options, thus informing clinical practices surrounding maternal-fetal health.
9) Disease:
In this study, 'disease' specifically refers to pre-eclampsia, a complication that affects pregnant women, characterized by hypertension and proteinuria. Understanding the mechanisms and biomarkers related to this disease enhances clinical care, supports early detection, and guides therapeutic interventions aimed at improving maternal and fetal outcomes.
10) Sharika (Sarika):
'Sarika' in this context likely relates to the authors or researchers involved in the study regarding the role of CUL1 and SEMA3B in pre-eclampsia. Highlighting contributors helps attribute scientific findings and encourages collaboration across research institutions in understanding pregnancy-related complications.
11) Nature:
'Nature' here could refer to the natural processes involved in pregnancy and the balance of angiogenic factors. Understanding the nature of these biological interactions is crucial for developing more effective strategies for monitoring and treating disorders such as pre-eclampsia affecting maternal and fetal health.
12) Rules:
'Rules' may denote the guidelines or protocols that govern ethical considerations, experimental design, and data analysis in medical research. Adherence to established rules ensures the integrity and validity of research findings, contributing to the development of robust clinical interventions in the healthcare setting.
13) Death:
'Death' refers to the serious consequences that can arise from conditions like pre-eclampsia, which can lead to maternal and fetal mortality. Understanding the risk factors and biological markers associated with this condition is essential for preventing adverse outcomes and improving maternal and child health.
14) Rana:
Similar to 'Sarika,' 'Rana' likely denotes a contributing researcher or a study author in this investigation of angiogenic factors in pre-eclampsia. Recognizing individual contributions fosters accountability and encourages an ongoing dialogue in the academic community regarding findings that impact public health priorities.
15) Discussion:
The 'discussion' section of the study typically interprets the findings, addresses limitations, and suggests future research directions. This critical analysis helps bridge the gap between raw data and practical applications, ensuring that scientific investigations translate effectively into understanding and addressing real-world health issues.
16) Developing:
'Developing' could refer to the progression of pre-eclampsia over time or the emergence of diagnostic and therapeutic strategies. Understanding how this condition develops necessitates continuous study of biological markers and their implications in managing risks associated with pregnancy-related complications.
17) Education:
'Education' pertains to informing healthcare professionals and patients about the implications of findings from studies like this one. Knowledge sharing is crucial for improving awareness of pre-eclampsia, its biomarkers, and the importance of early detection and intervention in protecting maternal and fetal health.
18) Edema (Oedema):
'Edema' refers to the swelling due to fluid retention, which can be a symptom of pre-eclampsia. Understanding the connections between edema and angiogenic factors can lead to better clinical assessments and management strategies that target underlying pathophysiological processes contributing to this pregnancy complication.
19) Birth:
'Birth' signifies the culmination of pregnancy and is critically impacted by conditions such as pre-eclampsia. Understanding the effects of angiogenic markers on maternal and fetal outcomes can shape clinical practices surrounding delivery methods and postnatal care to enhance safety and health for both mothers and infants.
20) Hand:
'Hand' may metaphorically refer to the role of healthcare providers in managing pre-eclampsia. The hands-on approach of physicians in collecting data, analyzing results, and taking action based on findings highlights the importance of direct involvement in improving maternal health outcomes.
21) Post:
'Post' likely relates to postpartum care and monitoring of both the mother and infant following delivery. Insights gained from studying pre-eclampsia biomarkers can inform post-birth strategies aimed at managing complications, ensuring ongoing health and recovery for both maternal and infant well-being.
Other Science Concepts:
Discover the significance of concepts within the article: ‘SEMA3B but Not CUL1 as Marker for Pre-Eclampsia Progression’. Further sources in the context of Science might help you critically compare this page with similair documents:
Vascular resistance, Spearman correlation test, Pro-angiogenic factors, Trophoblast Invasion, Protein Degradation.